SARS-CoV-2 3CLpro-IN-40

SARS-CoV-2 3CLpro-IN-40 (Compound 4a) (3.125-100 μM) exhibits low cytotoxicity in HEK-293 cells, with its CC₅₀ > 100 μM at all tested concentrations up to 100 μM^[1].
SARS-CoV-2 3CLpro-IN-40 (1.25-10 μM; 72 h post-virus adsorption) potently inhibits plaque formation of HCoV-OC43 in HCT-8 cells, with an IC₅₀ of 0.122 μM and a selectivity index >819.6^[1].
SARS-CoV-2 3CLpro-IN-40 (0.625-10 μM; 72 h) inhibits the replication of HCoV-OC43 in HCT-8 cells by reducing viral RNA levels in a dose-dependent manner^[1].
SARS-CoV-2 3CLpro-IN-40 (0.3125-20 μM) inhibits SARS-CoV-2 infection in Vero cells in a dose-dependent manner in vitro, reduces spike protein expression, and exhibits only extremely low cytotoxicity at concentrations up to 20 μM^[1].
SARS-CoV-2 3CLpro-IN-40 directly inhibits purified SARS-CoV-2 3CL^pro, with an IC₅₀ of 2.041 μM^[1].
SARS-CoV-2 3CLpro-IN-40 (1-10 μM) reduces the expression of proinflammatory cytokines induced by HCoV-OC43 in Calu-3 cells, and exerts significant inhibitory effects on IL-6, TNF-α and IFN-β at the concentration of 10 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.